How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,518 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Medical Treatment for Microscopic Colitis: A Community Hospital’s Experience Full Text available with Trip Pro

Medical Treatment for Microscopic Colitis: A Community Hospital’s Experience Lymphocytic colitis (LC) is a chronic disorder characterized by watery diarrhea. This study sought to evaluate if LC recurs after therapy, and the time frame in which this occurs. Secondary objectives included length and type of therapy, drug-free intervals, and reasons for drug discontinuation.A retrospective chart review between January 1, 2008 and October 30, 2015 of patients with biopsy-confirmed lymphocytic (...) from 4.7 to 2.4 compared to 5.8 to 2.8 for those given 5-aminosalicylic acid (5-ASA). First-line medications budesonide and 5-aminosalicylic acid failed in 12/58 (21%) of patients, other drugs also resulted in therapy changes. Thirty-five percent required their initial therapy changed and of those 40% required a second change. Symptom exacerbations were documented during therapy for 19% of patients; therapy changes resulted in good response.Almost half of all LC cases (56/114) gradually improved

2018 Gastroenterology research

102. Inulin-Type Fructan Supplementation of 3 to 6 Year-Old Children Is Associated with Higher Fecal Bifidobacterium Concentrations and Fewer Febrile Episodes Requiring Medical Attention. Full Text available with Trip Pro

Inulin-Type Fructan Supplementation of 3 to 6 Year-Old Children Is Associated with Higher Fecal Bifidobacterium Concentrations and Fewer Febrile Episodes Requiring Medical Attention. Inulin-type fructans used in formula have been shown to promote microbiota composition and stool consistency closer to those of breastfed infants and to have beneficial effects on fever occurrence, diarrhea, and incidence of infections requiring antibiotic treatment in infants.The primary study aim was to explore (...) whether prophylactic supplementation with prebiotic fructans is able to influence the frequency of infectious diseases in kindergarten children during a winter period. A secondary objective was to ascertain the effect on the intestinal microbiota.142 boys and 128 girls aged 3-6 y were randomly allocated to consume 6 g/d fructans or maltodextrin for 24 wk. At baseline, stool samples were collected for microbiota analysis and anthropometric measurements were made. During the intervention period

2018 Journal of Nutrition Controlled trial quality: uncertain

103. pK of a Novel 200 mg Ibuprofen Medicated Plaster

Official Title: A Single and Multiple Dose, Randomised, Open-label, Cross-over, Healthy Volunteer, Phase I Study of the Pharmacokinetics of a Novel 200 mg Ibuprofen Medicated Plaster Actual Study Start Date : September 25, 2018 Estimated Primary Completion Date : October 18, 2018 Estimated Study Completion Date : October 31, 2018 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Test IMP Drug: Ibuprofen (...) of the volunteers will be randomly assigned to one of 2 possible administration sequences. Condition or disease Intervention/treatment Phase Healthy Drug: Ibuprofen 200 mg TEPI Medicated Plaster Drug: Aktren® 200 mg überzogene Tabletten (Ibuprofen) Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 16 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment

2018 Clinical Trials

104. Bladder Antimuscarinic Medication and Accidental Bowel Leakage

: Severe constipation, fecal impaction or overflow fecal incontinence Inflammatory bowel disease, colorectal CA, spinal cord injury, multiple sclerosis, stroke, myasthenia gravis Infectious diarrhea Bothersome SUI (defined as "moderately" or greater bother on UDI-3) Patients planning to undergo surgery during study period Patients who are pregnant or intending to become pregnant during the study period Patients with contraindications to antimuscarinic medications (ie. closed angle glaucoma) Patients (...) on unstable or changing dosage of fiber or narcotics in the past 14 days Patients taking more than 2mg/day of loperamide (patients taking more than 2mg will be required a 2 week washout period) Patients currently taking medication for urgency urinary incontinence (these patients will also require a 2 week washout period) Patients initiating care with a pelvic floor physical therapist during the study period Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2018 Clinical Trials

105. Branched Chain Amino Acids Ratio in Medical Foods

Amino Acids in Medical Foods for Methylmalonic and Propionic Acidemias (MMA/PROP) Estimated Study Start Date : June 1, 2018 Estimated Primary Completion Date : May 31, 2019 Estimated Study Completion Date : May 31, 2019 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: BCAA Ratio Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different (...) parameters (3rd -85th percentiles for weight). Children with claustrophobia. Children currently or recently taking medication or antibiotics. Children with food allergies. Children who cannot speak, write and read in English Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov

2018 Clinical Trials

106. Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines

Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines CLINICAL PRACTICE GUIDELINES Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines † S. Rosell o 1 , I. Blasco 1 , L. Garc ia Fabregat 1 , A. Cervantes 1 & K. Jordan 2 , on behalf of the ESMO Guidelines Committee * 1 Medical Oncology Department, CIBERONC, Biomedical Research Institute INCLIVA, Valencia, Spain; 2 Department of Medicine V, Hematology (...) experience associated with the use of a medical product in a patient’ [5]. The European Medicines Agency (EMA) de?nes an ADR as a response to a medicinal product which is noxious and unintended and which occurs at doses nor- mally used in humans for the prophylaxis, diagnosis or therapy of disease or for the restoration, correction or modi?cation of physiological function [6]. An ADR may be classi?ed as: • A, Augmented pharmacological effects; • B, Bizarre; • C, Chronic effects; • D, Delayed effects; • E

2017 European Society for Medical Oncology

107. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. (Abstract)

Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Probiotics can be beneficial in irritable bowel syndrome (IBS). Mosapride citrate, a selective 5-HT4 receptor agonist, stimulates gastrointestinal motility. We investigated the efficacy of combination therapy with probiotics and mosapride for non-diarrheal-type IBS.Two hundred and eighty-five IBS patients were randomly (...) IBS, the improvements in stool frequency and consistency were significantly higher in the treatment groups 4 and 1, respectively, than those in the placebo group.Combination therapy with probiotics and mosapride is effective for relief of symptoms in patients with non-diarrheal-type IBS. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT01505777).© 2015 John Wiley & Sons Ltd.

2015 Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society Controlled trial quality: predicted high

108. Oral zinc supplementation for children with acute diarrhoea: a quasi-experimental study. (Abstract)

duration and frequency of diarrhoea. Secondary outcomes included changes in bodyweight, drugs side-effects, and episodes of any or severe dehydration. Data were analysed with SPSS. Outcome measures were compared with the Mann-Whitney U-test, student's t test, odds ratio, or χ2 test. The study was approved by the ministry of health and the Helsinki Committee in the Gaza Strip. Parents of the children provided verbally informed consent before participation.We enrolled 140 children (aged 1-120 months (...) Oral zinc supplementation for children with acute diarrhoea: a quasi-experimental study. Diarrhoea causes 15% of under-5 mortality in developing countries. Zinc (Zn) stores in the body are known to be depleted during acute diarrhoea. The aim of this study was to evaluate the efficacy of Zn given with standard treatment to children with acute or moderate diarrhoea.In this quasi-unmasked, parallel-group study, we enrolled children with diarrhoea at El-Dorra Paediatric Hospital, Gaza Strip

2018 Lancet Controlled trial quality: uncertain

109. Therapies Targeting the Nervous System for Chronic Pelvic Pain Relief

is by a multidisciplinary team potentially including those with expertise in hormonal, medical, invasive/ surgical and psychological therapeutic modalities. Although more invasive therapies should be reserved for patients who are refractory to standard treatment of any identified pathology or where no such * The International Association for the Study of Pain (IASP) no longer recommends the use of the term interstitial cystitis (IC), having replaced it with the more correct bladder pain syndrome (BPS). However (...) in at least partly alleviating pain, would be expected to improve quality of life and may help to prevent the development of long-lasting central changes. 2. Medical treatments 2.1 Antidepressant and anticonvulsant medication Antidepressant and anticonvulsant drugs have been a mainstay of the management of chronic pain, particularly neuropathic pain, for many years, 9–13 although the mechanisms of action are not completely understood. It appears that antidepressants act by altering activity within pain

2015 Royal College of Obstetricians and Gynaecologists

110. Recommendations for the control of multi-drug resistant gram-negatives - carbapenem resistant enterobacteriaceae

screened for CRE, until results of screening are negative. 3.2.2 All patients with CRE should be managed using contact precautions in a single room with their own toilet facilities. If a single room is not available: ? ? Prioritise single rooms for those at highest risk of secondary transmission, such as those who have diarrhoea or are incontinent (urine or faeces), those who have wounds with uncontrolled drainage and those with medical devices in situ. ? ? CRE positive patients should not be grouped (...) and practitioners may be assisted by use of an inter-facility or community transfer form, in addition to verbal communications. This should include information on whether the patient has been colonised and/or infected with CRE or other multi-drug resistant organisms, the dates and results of any relevant clinical and/or surveillance cultures and an assessment of the risk of secondary transmission (taking into account conditions such as diarrhoea or incontinence of urine or faeces, wounds with uncontrolled

2014 Clinical Practice Guidelines Portal

111. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

storage disease type I (GSD I) after reviewing the autopsy reports of two children whose livers and kidneys contained excessive amounts of Submitted 12 August 2014; accepted 12 August 2014; advance online publication 6 November 2014. doi:10.1038/gim.2014.128 Genet Med 00 00 2014 Genetics in Medicine 10.1038/gim.2014.128 ACMG Standards and Guidelines 00 00 12August2014 12August2014 © American College of Medical Genetics and Genomics 6November2014 Purpose: Glycogen storage disease type I (GSD I (...) , Durham, North Carolina, USA; 2 Division of Metabolic Disorders, Children’ s Hospital of Orange County, Orange, California, USA; 3 Division of Genetics, Nemours Children’ s Clinic, Jacksonville, Florida, USA; 4 Departments of Pediatrics and Medicine, Columbia University Medical Center, New Y ork, New Y ork, USA; 5 Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA; 6 Department of Medicine, University of W ashington, Seattle, W ashington, USA; 7 Division

2014 American College of Medical Genetics and Genomics

112. Medical Management of Kidney Stones

. Diet therapy has never been compared head-to-head with pharmacologic therapy. As such, recommendations by the Panel incorporate drugs and/or diet therapy in select circumstances, until the superiority of one over the other can be demonstrated and to allow individualization for particular patients. Evaluation Guideline Statement 1 A clinician should perform a screening evaluation consisting of a detailed medical and dietary history, serum chemistries and urinalysis on a patient newly diagnosed (...) Safety and Quality of Care Accreditations and Reporting Patient Education Medical Management of Kidney Stones (2014) Published 2014 The purpose of the clinical guideline on Medical Management of Kidney Stones is to provide a clinical framework for the diagnosis, prevention and follow-up of adult patients with kidney stones based on the best available published literature. Topics covered include evaluation, diet therapy, pharmacologic therapy, and follow-up. [pdf] Panel Members Margaret Sue Pearle, MD

2014 American Urological Association

113. Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients

patients. Condition or disease Intervention/treatment Phase Melanoma Drug: TIL + IL-2 + Nivolumab Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 11 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients: Pilot Study Phase I/II Actual Study Start Date (...) , http://ctep.cancer.gov) Secondary Outcome Measures : Efficacy of adoptive T cell therapy associated to intravenous injections of Nivolumab [ Time Frame: At 12 months ] The overall tumor response will be evaluated according to the guidelines for Response Evaluation Criteria in Solid Tumors (RECIST1.1) and immune-related Response Criteria (irRC) Duration of the clinical response [ Time Frame: Within 12 months of follow-up ] Time interval between the evaluation of the first objective response

2017 Clinical Trials

114. Traditional Chinese medicine for treating HIV-related diarrhea: a systematic review and meta-analysis of clinical trials

Traditional Chinese medicine for treating HIV-related diarrhea: a systematic review and meta-analysis of clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence (...) by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about

2017 PROSPERO

115. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203 Full Text available with Trip Pro

or almost constant diarrhea ( P = .01), and more patients who received standard RT were taking antidiarrheal medications four or more times daily (20.4% v 7.8%; P = .04). Conclusion Pelvic IMRT was associated with significantly less GI and urinary toxicity than standard RT from the patient's perspective. (...) Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203 Purpose NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and health-related quality of life during treatment with standard pelvic radiation or intensity-modulated radiation therapy (IMRT) in women with cervical and endometrial cancer. Methods Patients were randomly assigned to standard four-field radiation therapy (RT) or IMRT radiation treatment. The primary end

2018 EvidenceUpdates

116. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer (Abstract)

inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression (...) 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.

2018 EvidenceUpdates

117. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE Full Text available with Trip Pro

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast (...) cancer. We hypothesized that everolimus plus the selective ER downregulator fulvestrant would be more efficacious than fulvestrant alone in ER-positive metastatic breast cancer resistant to aromatase inhibitor (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131 postmenopausal women with ER-positive, human epidermal growth factor receptor 2-negative, AI-resistant metastatic breast cancer randomly assigned to fulvestrant (500 mg days 1

2018 EvidenceUpdates

118. Diarrhoea - adult's assessment

. Other causes include drugs, anxiety, food allergy, and acute appendicitis. Causes of chronic diarrhoea include irritable bowel syndrome, diet, inflammatory bowel disease, coeliac disease, and bowel cancer. Diarrhoea is one of the most common symptoms for which people seek medical advice. Assessment for acute and chronic diarrhoea should include: Determining onset, duration, frequency, and severity of symptoms. Identifying red flag symptoms. Ascertaining the underlying cause. Looking (...) age (people 60 years of age or older are more at risk of complications). Home circumstances and level of support. Fever. Bloody diarrhoea. Abdominal pain and tenderness. Increased risk of poor outcome, for example: Coexisting medical conditions — immunodeficiency, lack of stomach acid, inflammatory bowel disease, valvular heart disease, diabetes mellitus, renal impairment, rheumatoid disease, systemic lupus erythematosus. Drugs — immunosuppressants or systemic steroids, proton pump inhibitors

2018 NICE Clinical Knowledge Summaries

119. Guidelines for the Clinical and Operational Management of Drug-Resistant Tuberculosis

medicines 230 Importation of drug-resistant tuberculosis medicines 231 Storage and distribution in-country 231 Rational use 231 References 232 Appendices 233 CONTENTS viiAbbreviations 2LI second-line injectable drug AFB acid-fast bacillus Am amikacin Amx/Clv amoxicillin/clavulanate ART antiretroviral therapy ARV antiretroviral (drug) ATS American Thoracic Society AUC24 area under the concentration-time curve from 0 to 24 h BTS British Thoracic Society CD4 cells CD4+T lymphocytes Cf clofazimine Cfx cipro (...) . It was seen following the introduction of widespread anti- microbial use in the late 1940s and early 1950s, and served as a basis for the development of multidrug therapy for TB by Crofton and his colleagues in Edinburgh. When investigators introduced new drugs for treatment of TB as they were developed, they found that the bacterial populations selected by the treatment were resistant to the medications that had previously been used. Whereas the initial appearance of drug resistance is a ‘man-made’ phe

2013 International Union Against TB and Lung Disease

120. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

approaches to HIV prevention to achieve maximum impact on reducing HIV transmission and acquisition. ART (ANTIRETROVIRAL THERAPY) ARV (antiretroviral) drugs refer to the medicines themselves and not to their use. ART refers to the use of a combination of three or more Ar V drugs to achieve viral suppression. This generally refers to lifelong treatment. Synonyms are combination Ar T and highly active Ar T. ART for prevention is used to describe the HIV prevention benefits of A r T. Eligible for ART refers (...) Library Cataloguing-in-Publication Data Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: r ecommendations for a public health approach June 2013. 1.HIV infections – drug therapy. 2.HIV infections – prevention and control. 3.Anti-r etroviral agents – therapeutic use. 4.Guideline. I.World Health Organization. ISBN 978 92 4 150572 7 (NLM classification: WC 503.2) © World Health Organization 2013 All rights reserved. Publications of the World Health

2013 World Health Organisation HIV Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>